GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Bangkok Lab and Cosmetic PCL (BKK:BLC) » Definitions » EBIT

Bangkok Lab and Cosmetic PCL (BKK:BLC) EBIT : ฿208 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bangkok Lab and Cosmetic PCL EBIT?

Bangkok Lab and Cosmetic PCL's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ฿54 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ฿208 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bangkok Lab and Cosmetic PCL's annualized ROC % for the quarter that ended in Mar. 2024 was 16.45%. Bangkok Lab and Cosmetic PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 22.50%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bangkok Lab and Cosmetic PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 8.35%.


Bangkok Lab and Cosmetic PCL EBIT Historical Data

The historical data trend for Bangkok Lab and Cosmetic PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Lab and Cosmetic PCL EBIT Chart

Bangkok Lab and Cosmetic PCL Annual Data
Trend Dec21 Dec22 Dec23
EBIT
88.94 172.87 200.23

Bangkok Lab and Cosmetic PCL Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.52 36.75 51.08 65.88 53.86

Competitive Comparison of Bangkok Lab and Cosmetic PCL's EBIT

For the Household & Personal Products subindustry, Bangkok Lab and Cosmetic PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bangkok Lab and Cosmetic PCL's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Bangkok Lab and Cosmetic PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bangkok Lab and Cosmetic PCL's EV-to-EBIT falls into.



Bangkok Lab and Cosmetic PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿208 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bangkok Lab and Cosmetic PCL  (BKK:BLC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bangkok Lab and Cosmetic PCL's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=215.456 * ( 1 - 17.93% )/( (1094.855 + 1055.197)/ 2 )
=176.8247392/1075.026
=16.45 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2240.253 - 169.909 - ( 975.489 - max(0, 442.266 - 1744.033+975.489))
=1094.855

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2212.335 - 201.657 - ( 955.481 - max(0, 376.172 - 1704.127+955.481))
=1055.197

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bangkok Lab and Cosmetic PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=215.456/( ( (415.306 + max(562.295, 0)) + (425.685 + max(512.141, 0)) )/ 2 )
=215.456/( ( 977.601 + 937.826 )/ 2 )
=215.456/957.7135
=22.50 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(346.5 + 392.827 + 6.8899999999999) - (169.909 + 0 + 14.013)
=562.295

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(326.907 + 396.005 + 5.143) - (201.657 + 0 + 14.257)
=512.141

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bangkok Lab and Cosmetic PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=207.572/2484.689
=8.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bangkok Lab and Cosmetic PCL EBIT Related Terms

Thank you for viewing the detailed overview of Bangkok Lab and Cosmetic PCL's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bangkok Lab and Cosmetic PCL (BKK:BLC) Business Description

Traded in Other Exchanges
N/A
Address
Nong Chae Sao Road, No. 48/1 Moo 5, Nam Phu, Mueang Ratchaburi, Ratchaburi, Bangkok, THA, 70000
Bangkok Lab and Cosmetic PCL are one of Thailand's comprehensive healthcare solutions groups. Its operation covers the complete value chain of the healthcare business. Its product portfolio comprises generic and new generic drugs, herbal medicines, animal medicines, cosmetics, food supplements, and other health products. Its operation ranges from research and development, manufacturing with international standards, sales, and marketing, to distribution to partnering businesses and customers.

Bangkok Lab and Cosmetic PCL (BKK:BLC) Headlines

No Headlines